Status:
COMPLETED
Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler
Lead Sponsor:
AstraZeneca
Conditions:
Stable Asthma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to compare the therapeutic effects of formoterol in Symbicort with formoterol in Oxis Turbuhaler for the treatment of adults with stable asthma.
Eligibility Criteria
Inclusion
- At least 18 years of age
- Diagnosis of asthma and baseline lung function tests as determined by the protocol
- Required and received treatment with inhaled corticosteroids within timeframe and doses specified in the protocol
Exclusion
- Severe asthma
- Has required treatment with any non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in protocol or requires treatment with beta-blockers
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2003
Estimated Enrollment :
175 Patients enrolled
Trial Details
Trial ID
NCT00658255
Start Date
October 1 2002
End Date
May 1 2003
Last Update
January 24 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.